912770-13-9

Basic information

• Product Name: Imidazo[2,1-b]thiazole-3-carboxylic acid, 6-(2-nitrophenyl)-
• CAS NO: 912770-13-9
• Molecular Formula: C12H7N3O4S
• Molecular Weight: 289.271
• Mol File: 912770-13-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Imidazo[2,1-b]thiazole-3-carboxylic acid, 6-(2-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[2,1-b]thiazole-3-carboxylic acid, 6-(2-nitrophenyl)-(912770-13-9)
• EPA Substance Registry System: Imidazo[2,1-b]thiazole-3-carboxylic acid, 6-(2-nitrophenyl)-(912770-13-9)

Safety Data

• Hazardous Substances Data: 912770-13-9(Hazardous Substances Data)

Upstream product

• 6851-99-6 2-bromo-1-(2-nitrophenyl)ethanone 
• 925437-84-9 6-(2-nitrophenyl)-imidazo[2,1-b]thiazole-3-carboxylic acid ethyl ester 

Downstream Products

• 925437-85-0 (6-(2-nitrophenyl)imidazo[2,1-b]thiazol-3-yl)methanol 
• 925437-87-2 4-[6-(2-aminophenyl)imidazo[2,1-b]thiazol-3-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester 
• 1093403-37-2 C₁₃H₁₁N₃O₅S₂ 
• 925436-46-0 C₃₀H₃₁N₇O₃S 
• 925434-55-5 SRT1720 
• 925438-48-8 3-chloromethyl-6-(2-nitro-phenyl)-imidazo[2,1-b]thiazole 
• 1093403-45-2 2-(3-[1,2,4]triazol-1-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenylamine 
• 1093403-44-1 6-(2-nitro-phenyl)-3-[1,2,4]triazol-1-ylmethyl-imidazo[2,1-b]thiazole 
• 1056562-54-9 2-(3-morpholin-4-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenylamine 
• 1093403-43-0 4-methyl-2-pyridin-3-yl-thiazole-5-carboxylic acid [2-(3[1,2,4]triazol-1-ylmethyl-imidazo[2,1-b]thiazol-6-yl)-phenyl]-amide 
• 1093403-33-8 SRT₂₁₀₄ 

Relevant articles and documents

Discovery of imidazo[1,2-6]thiazole derivatives as novel SIRT1 activators

A series of imidazo[1,2-b]thiazole derivatives is shown to activate the NAD+-dependent deacetylase SIRT1, a potential new therapeutic target to treat various metabolic disorders. This series of compounds was derived from a high throughput scree

SIRTUIN POLYMORPHISMS AND METHODS OF USE THEREOF

Provided herein are methods for diagnosis and prognosis using polymorphic variants of sirtuins. Such polymorphic may be used, for example, to identify subjects that would be responsive to treatment with a sirtuin modulating compound andor subjects that are suffering from or susceptible to a disease mediated by a sirtuin. Also provided are methods for determining the predictive value of a sirtuin polymorphic variant, methods for evaluating sirtuin modulating compounds, and methods for determining appropriate dosage andor treatment regimens for subjects having one or more sirtuin polymorphic variants. Screening methods for identifying sirtuin modulating compounds using polymorphic variants of a sirtuin are also provided.